Charcot-Marie-Tooth disease type 1F (CMT1F) is a rare inherited nerve disease that mainly affects the long nerves in the arms and legs. It is part of the big Charcot-Marie-Tooth (CMT) group of hereditary peripheral neuropathies, which means the problem lies in the nerves outside the brain and spinal cord. In CMT1F, the outer insulation of the nerve (the myelin sheath) is damaged, so doctors call it a “demyelinating” neuropathy. This damage causes very slow nerve signals, weakness of the feet and legs, problems with walking, loss of feeling, and reduced reflexes. Orpha+1
Charcot-Marie-Tooth disease type 1F is a rare inherited nerve disease that mainly affects the long nerves in the arms and legs. In many people it is linked to a change (mutation) in a gene called INF2, which affects the support cells of nerves (Schwann cells) and can also affect the kidney filters (causing a problem called focal segmental glomerulosclerosis, FSGS). This gene change leads to damage of the myelin coating around nerves, so signals travel more slowly and muscles become weak and thin over time.Wiley Online Library+3PubMed+3
CMT1F is caused by disease-causing changes (mutations) in a gene called NEFL on chromosome 8 (8p21.2). The NEFL gene gives instructions for making neurofilament light chain, a key structural protein inside nerve cells and axons. When NEFL is not built correctly, the internal support of the nerve becomes unstable and the nerve cannot keep its normal shape and function. This leads to chronic damage of the long motor and sensory nerves and a slow, progressive neuropathy. Orpha+1
CMT1F usually follows an autosomal dominant pattern. This means one changed copy of NEFL from either parent is enough to cause disease. In some families, a new mutation appears for the first time in a child with no previous family history. Symptoms can start in early childhood with delayed walking, clumsiness, or frequent falls, but some people develop symptoms later in adult life and have milder weakness. The severity can be very different even inside the same family, from mild walking problems to severe disability requiring walking aids or a wheelchair. Genetic Diseases Center+2MalaCards+2
CMT1F is part of a wider NEFL-related CMT spectrum. The same NEFL gene can cause both demyelinating CMT (CMT1F) and axonal CMT (CMT2E) as well as “intermediate” forms. Doctors separate them mainly by nerve conduction study results: very slow conduction suggests CMT1F, while normal or only mildly slowed conduction suggests CMT2E. This overlap explains why some people with NEFL mutations show mixed features and why genetic testing is very important to confirm the exact diagnosis. PMC+2jnnp.bmj.com+2
Other names
CMT1F has been described in the medical literature under several different names. Knowing these names can help when searching scientific papers or genetic test reports because different sources may use different terms for the same condition. Genetic Diseases Center+1
Some other names and closely related terms include:
Charcot-Marie-Tooth disease, demyelinating, type 1F
Hereditary motor and sensory neuropathy type 1F (HMSN I F)
NEFL-related demyelinating Charcot-Marie-Tooth disease
NEFL-related CMT1F / CMT2E spectrum
NEFL-associated hereditary neuropathy
These names all refer to the same underlying problem: a hereditary peripheral neuropathy caused by mutations in the NEFL gene, with predominantly demyelinating features when classified as CMT1F. Orpha+2MalaCards+2
Types of Charcot-Marie-Tooth disease type 1F
Doctors do not have “formally separate” types of CMT1F the way they do for different CMT subtypes like CMT1A, CMT1B, etc. However, based on age of onset, severity, and nerve test results, experts often describe several clinical patterns within NEFL-related CMT1F. This helps explain why some people are severely affected and others are mild even with a mutation in the same gene. PMC+1
Early-onset severe CMT1F – Symptoms start in infancy or early childhood. Children may walk late, fall often, and quickly develop marked foot deformities and distal leg weakness. Nerve conduction velocities are usually very slow, indicating strong demyelination. Genetic Diseases Center+1
Childhood-onset moderate CMT1F – Many people develop noticeable weakness and sensory loss in primary-school years. They can usually walk but have difficulty running, climbing stairs, or keeping up with peers. Foot deformities, such as high arches and hammertoes, slowly become more obvious over time. Genetic Diseases Center+1
Adolescent- or adult-onset mild CMT1F – Some individuals do not notice clear symptoms until teenage years or adulthood, when they begin to have ankle sprains, fatigue, or subtle balance problems. Weakness may remain mild and progress slowly, so they might never need a wheelchair. Global Genes+1
Intermediate NEFL-related CMT (overlap with CMT2E) – In some patients, nerve conduction studies show values between typical demyelinating and typical axonal ranges. Clinically, they may have a mix of demyelinating and axonal features. These cases form part of the CMT2E/1F spectrum but are often grouped clinically with CMT1F because of demyelinating signs. PMC+1
NEFL-related CMT with unusual features – Research has shown that NEFL mutations can sometimes be linked with additional symptoms such as cardiologic or urinary problems or central nervous system signs, although these are not typical. These cases are rare but show how broad the clinical range of NEFL-related neuropathy can be. PubMed+1
Causes of Charcot-Marie-Tooth disease type 1F
The direct cause of CMT1F is a disease-causing mutation in the NEFL gene. There are not 20 completely different primary causes, but there are many related genetic and biological factors that explain why the disease appears and how it behaves. Below, each point describes either the main cause or a contributing factor that can influence severity, onset, or presentation. Orpha+1
NEFL gene mutation – The key cause is a pathogenic variant in the NEFL gene, which encodes the neurofilament light chain. Changes in this gene alter the structure or function of neurofilaments, leading directly to CMT1F. Orpha+1
Autosomal dominant inheritance – In most families, a single mutated copy of NEFL inherited from an affected parent is enough to produce disease. This dominant transmission pattern explains why multiple generations may be affected. MalaCards+1
De novo mutation – In some individuals, the NEFL mutation appears for the first time in the child and is not present in either parent. This new (de novo) mutation is still the main cause of disease in that person. NCBI+1
Abnormal neurofilament assembly – The mutation can disturb how neurofilament proteins assemble into stable filaments. Misassembled filaments may clump inside the axon, blocking normal transport and damaging the nerve. PMC+1
Axonal transport disruption – Neurofilaments help maintain the structure of long axons and support transport of nutrients and cell components. When NEFL is faulty, axonal transport slows, making long nerves in the legs and arms especially vulnerable. PMC+1
Secondary demyelination – Although NEFL is mainly an axonal protein, its malfunction can indirectly disturb the myelin sheath, leading to demyelination and very slow nerve conduction velocities, which define CMT1F. Orpha+1
Giant axon formation – Some NEFL mutations cause abnormal swelling of axons (giant axons) filled with neurofilament aggregates. These changes weaken signal conduction and damage peripheral nerves. NCBI+1
Onion bulb formation in nerves – Nerve biopsies in some CMT1F patients show onion bulb formations, where Schwann cells repeatedly attempt to remyelinate damaged axons. This structural change reflects long-standing demyelination. Nature+1
Genetic background (modifier genes) – Other genetic factors may modify how severe the NEFL mutation appears. Differences in additional nerve-related genes can help explain why one person is severely affected and another is mild with the same NEFL variant. PMC+1
Type of NEFL mutation – Different NEFL variants (for example, missense changes at specific positions) lead to different phenotypes. Some mutations are linked with early severe disease, while others cause milder, late-onset neuropathy. Wiley Online Library+1
Gene dosage effects – Although classically CMT1F is dominant, rare cases with more complex inheritance suggest that the amount of mutant versus normal NEFL protein may influence clinical severity. MalaCards+1
Environmental stress on nerves – While not a primary cause, repeated mechanical stress, poor footwear, or frequent ankle injuries can worsen symptoms in already fragile peripheral nerves. NCBI+1
Coexisting neuropathy risk factors – Diabetes, vitamin deficiencies, or alcohol misuse do not cause CMT1F, but if present they may add extra nerve damage on top of the genetic neuropathy and make symptoms worse. NCBI+1
Age-related nerve degeneration – As everyone ages, nerves gradually lose some function. In people with NEFL mutations, this normal aging process may join with the genetic weakness and speed up progression in later life. NCBI+1
Immune or inflammatory responses – Some researchers suggest that chronic damage in hereditary neuropathies might trigger mild secondary immune responses in nerves, which could further affect myelin and axons, although this is not the primary cause. NCBI
Mitochondrial stress in axons – Poor axonal structure and transport can strain the tiny energy factories (mitochondria) in nerve fibers, lowering energy supply for long nerves and contributing to their gradual failure. PMC+1
Impaired cytoskeleton interactions – Neurofilaments interact with other structural proteins like microtubules. NEFL mutations can disturb these interactions, making axons less stable and easier to damage. PMC+1
Developmental vulnerability of long nerves – During childhood growth, long axons in the legs and arms lengthen quickly. In children with CMT1F, these rapidly growing nerves may be especially sensitive to the effects of NEFL mutations, explaining early onset in many patients. Genetic Diseases Center+1
Mechanical imbalance from foot deformities – Once foot deformities such as cavus foot develop, the abnormal loading of joints and muscles can cause further nerve compression or stretching, increasing functional disability. NCBI
Lack of nerve regeneration capacity – Peripheral nerves can sometimes regenerate after injury, but in hereditary neuropathies the ongoing genetic problem limits full repair. Over time, repeated damage without complete healing leads to progressive weakness and sensory loss. NCBI+1
Symptoms of Charcot-Marie-Tooth disease type 1F
Symptoms of CMT1F usually develop slowly over years. They mostly affect the feet and legs, and later the hands and arms. The severity and age of onset vary widely, even in the same family, because NEFL-related CMT is clinically very heterogeneous. Genetic Diseases Center+1
Distal leg weakness – The earliest and most typical sign is weakness of the muscles around the ankles and feet. People may find it hard to stand on their toes or heels, climb stairs, or run. Genetic Diseases Center+1
Foot drop and high-stepping gait – Weakness of the muscles that lift the foot causes the toes to drag during walking. To avoid tripping, the person lifts the knees higher than usual, leading to a “steppage” or high-stepping gait. NCBI+1
Frequent tripping and falls – Because the feet do not lift properly and balance is poor, patients may stumble on small obstacles or uneven ground, especially in dim light. Genetic Diseases Center+1
Foot deformities (pes cavus, hammertoes) – Over time, imbalance between strong and weak foot muscles leads to high-arched feet, curved toes, and other deformities. These changes can make shoe fitting difficult and raise the risk of pressure sores. NCBI+1
Distal muscle wasting (atrophy) – The small muscles of the feet, lower legs, and later hands become thin, giving the legs a characteristic “inverted champagne bottle” shape. MalaCards+1
Numbness and reduced sensation – Many patients notice reduced feeling for touch, pain, temperature, or vibration in the feet and hands. This sensory loss can cause difficulty feeling the ground or noticing injuries. Genetic Diseases Center+1
Tingling or burning sensations – Abnormal nerve firing may cause unpleasant sensations such as tingling, pins and needles, or burning in the feet and legs, sometimes described as neuropathic pain. NCBI+1
Absent or reduced tendon reflexes – Reflexes at the ankles and knees are often weak or absent when the doctor tests them with a reflex hammer, reflecting damage of the reflex arc in the peripheral nerves. Genetic Diseases Center+1
Hand weakness and fine motor problems – As the disease progresses, the small muscles of the hands may weaken. Patients may have trouble with buttons, zippers, handwriting, or holding small objects. NCBI+1
Balance difficulties – Loss of position sense in the feet and weakness of ankle muscles make it hard to keep balance, especially in the dark or on uneven surfaces. Some people need support such as a cane or walker. Wiley Online Library+1
Fatigue and reduced endurance – Walking with weak muscles and deformities requires more energy. Many patients feel tired after short distances or standing for long periods. NCBI+1
Leg and foot cramps – Some individuals experience painful cramps in calf or foot muscles, especially at night or after activity, due to nerve dysfunction and muscle overwork. NCBI+1
Slow progression over many years – CMT1F usually progresses slowly. Symptoms may gradually worsen over decades, but the rate varies widely from person to person. Genetic Diseases Center+1
Mild scoliosis or posture changes – In some children, chronic muscle imbalance and weakness can lead to curvature of the spine or altered posture, though this is not present in every case. Wiley Online Library+1
Emotional and social impact – Long-term physical disability, visible foot deformities, and need for assistive devices can affect self-confidence, mood, and social activities, especially in adolescents and young adults. Wiley Online Library+1
Diagnostic tests for Charcot-Marie-Tooth disease type 1F
Diagnosing CMT1F requires a combination of clinical examination, nerve tests, and genetic studies. The goal is to show that a chronic hereditary demyelinating neuropathy is present and to identify a disease-causing mutation in the NEFL gene. Below, tests are grouped into physical examination, manual clinical tests, laboratory and pathological tests, electrodiagnostic tests, and imaging tests. NCBI+1
Physical examination tests
1. Full neurological examination – The doctor carefully checks muscle strength, reflexes, sensation, coordination, and gait. In CMT1F, the exam typically shows distal muscle weakness and wasting, reduced or absent reflexes, and sensory loss in a stocking-glove pattern, especially in the feet and lower legs. Genetic Diseases Center+1
2. Gait and posture assessment – Watching the way the patient walks and stands helps identify high-stepping gait, foot drop, difficulty with heel-toe walking, and problems with balance. These signs are typical for CMT and help distinguish it from other causes of weakness. NCBI+1
3. Foot and hand deformity inspection – The examiner looks for pes cavus, hammertoes, clawing of toes, and hand muscle wasting. The pattern and symmetry of deformities support a diagnosis of hereditary neuropathy rather than an isolated orthopedic problem. NCBI+1
4. Reflex testing – Using a reflex hammer, the doctor tests Achilles, knee, and upper-limb reflexes. Absent ankle reflexes are very common in CMT1F and can appear early in the disease, even before severe weakness. Genetic Diseases Center+1
Manual bedside tests
5. Manual muscle testing (MRC grading) – The examiner grades strength of individual muscle groups (for example ankle dorsiflexion, plantarflexion, hand grip) using the Medical Research Council (MRC) scale from 0 to 5. This simple manual test helps document severity and progression over time. NCBI+1
6. Sensory testing with simple tools – Light touch with cotton, pinprick with a disposable pin, and vibration using a tuning fork check different sensory pathways. In CMT1F, vibration and position sense are often reduced in the feet first. NCBI+1
7. Romberg test for balance – The patient stands with feet together and then closes the eyes. Increased swaying or loss of balance suggests impaired proprioception due to sensory neuropathy, which is common in CMT1F. NCBI+1
8. Heel-toe walking test – Asking the patient to walk on heels, then on toes, is a simple way to look for weakness in ankle dorsiflexors and plantarflexors. Difficulty or inability to perform these tasks is typical in distal neuropathies like CMT. NCBI+1
Laboratory and pathological tests
9. Genetic testing for NEFL mutations – Molecular analysis of the NEFL gene is the key confirmatory test. Targeted sequencing of NEFL or inclusion in a multigene CMT panel can detect pathogenic variants that define CMT1F and related NEFL-associated neuropathies. PreventionGenetics+1
10. Extended CMT gene panel or exome sequencing – Because more than 100 genes can cause CMT, many centers use next-generation sequencing panels or whole-exome sequencing to search for mutations in NEFL and other CMT genes at the same time, improving diagnostic yield. NCBI+1
11. Basic blood tests to rule out acquired neuropathies – Tests like fasting glucose, HbA1c, vitamin B12, folate, thyroid function, and kidney and liver function are used to exclude treatable acquired causes of neuropathy that might coexist with or mimic hereditary CMT. NCBI+1
12. Nerve biopsy (rarely needed) – In selected cases, a small sample of peripheral nerve (often sural nerve) may be taken to examine under the microscope. In CMT1F, biopsy can show demyelination, onion bulb formations, and sometimes giant axons with neurofilament accumulation, supporting a hereditary demyelinating neuropathy. Nature+1
13. Cerebrospinal fluid (CSF) analysis – CSF examination is not routinely required but may be done to exclude inflammatory neuropathies like CIDP. In hereditary CMT, CSF protein is usually normal or only mildly elevated, helping distinguish CMT from acquired immune neuropathies. NCBI+1
Electrodiagnostic tests
14. Nerve conduction studies (NCS) – This is one of the most important tests for CMT1F. Small electrical pulses are applied over nerves and the responses are recorded. In demyelinating CMT, motor nerve conduction velocities are markedly slowed, often below 38 m/s, with prolonged distal latencies. This pattern supports a diagnosis of CMT1 rather than CMT2. NCBI+1
15. Electromyography (EMG) – A fine needle electrode inserted into muscles records electrical activity. EMG in CMT1F typically shows chronic denervation and reinnervation patterns, confirming that the weakness comes from peripheral nerve damage rather than muscle disease. NCBI+1
16. F-wave and late response studies – These specialized parts of nerve conduction studies evaluate the whole length of motor nerves, including proximal segments. Abnormal F-waves in CMT1F further support widespread demyelinating neuropathy. NCBI+1
Imaging tests
17. X-ray of feet and spine – Simple X-rays show bone changes from long-standing deformities, such as high arches, hammertoes, or scoliosis. Although X-rays cannot see nerves, they help orthopedic planning for braces or surgery if needed later. NCBI+1
18. Magnetic resonance imaging (MRI) of peripheral nerves or spine – MRI can sometimes show thickened peripheral nerves in hereditary neuropathies and can rule out spine problems such as disk disease that might mimic neuropathy symptoms. Specialized nerve MRI is mainly available in larger centers. NCBI+1
19. Ultrasound of peripheral nerves – High-resolution ultrasound can visualize nerve size and structure. In CMT, nerves may look enlarged or have altered patterns. This non-invasive technique is increasingly used as an additional tool to support the diagnosis. NCBI+1
20. Gait and movement analysis with video or motion systems – In some specialized clinics, computer-assisted gait analysis is used to quantify stride length, speed, and joint angles. This helps document the functional impact of CMT1F and evaluate the effect of orthoses or therapy over time. Wiley Online Library+1
Non-pharmacological treatments and therapies
These treatments use no medicines. They support muscles, joints, nerves, and daily life. Most people with CMT benefit from a mix of several of these.Muscular Dystrophy Association+4nhs.uk+4Mayo Clinic+4
Regular physical therapy (physiotherapy)
A physiotherapist designs exercises to keep muscles strong and flexible. They usually focus on feet, ankles, knees, and hands. Gentle strengthening, stretching, and balance work can slow stiffness and reduce the risk of contractures and falls. Therapy is usually repeated every week or month and adjusted as the disease changes.Occupational therapy (OT)
An occupational therapist helps you manage daily activities like dressing, writing, using a computer, cooking, or school tasks. They suggest easier ways to do tasks and may recommend special tools (adaptive equipment), so you can stay independent for as long as possible.Ankle-foot orthoses (AFOs) and braces
AFOs are lightweight plastic or carbon braces worn inside or around shoes. They hold the ankle and foot in a better position, help lift the toes, and reduce “foot drop” and tripping. Studies and expert guidelines show that AFOs can improve walking speed, balance, and confidence in many people with CMT.Charcot-Marie-Tooth Association+2Mayo Clinic+2Custom shoes and shoe inserts
Special shoes, high-top shoes, or custom insoles support weak feet and ankles and spread pressure more evenly. This can reduce foot pain and skin breakdown and may delay deformities such as high arched feet (pes cavus).Hand splints and adaptive hand devices
When hand muscles become weak, soft splints or functional hand braces help straighten fingers and improve grip. Adaptive pens, larger handles, and special keyboards can make writing and computer use easier, reducing fatigue.Stretching to prevent contractures
Daily stretching of calves, hamstrings, and feet helps keep joints moving and reduces the chance that joints “freeze” into a fixed position (contracture). Gentle, slow stretches held for 20–30 seconds, under guidance from a therapist, are safer than fast or forceful stretches.Strength training with low resistance
Supervised, low-to-moderate strength training can help maintain muscle power without over-tiring weak nerves. The exercises are usually done with bands or light weights and many rest breaks. Over-heavy training can damage already fragile nerves, so guidance from a therapist is important.MDPI+1Balance and gait training
Balance exercises, such as standing on different surfaces, stepping practice, and safe obstacle walking, reduce falls. Gait training teaches safer foot placement and better posture during walking. This therapy is especially helpful in teenagers as their height and weight change quickly.Walking aids (canes, crutches, walkers)
If braces and therapy are not enough, a cane or walker may help. These tools make walking more stable, reduce fear of falling, and allow people to walk longer distances with less fatigue.Home and school environment modifications
Simple changes like removing loose rugs, installing grab bars, using non-slip mats, and adjusting furniture height reduce fall risk. At school or work, using elevators, special desks, or scheduling rest breaks can make life easier and safer.Pain psychology and cognitive-behavioural therapy (CBT)
Chronic pain and disability can cause stress, anxiety, and low mood. Working with a psychologist trained in pain or chronic illness can teach coping skills, relaxation, pacing, and sleep hygiene, which can reduce the impact of pain and fatigue.Energy conservation and fatigue management
People with CMT often get tired easily. Learning to pace activities, sit instead of stand, use rolling bags, and plan rest periods can help save energy for important school, work, or family tasks.Respiratory and speech therapy (if needed)
In some advanced or rare cases, breathing or voice muscles may be affected. Breathing exercises, cough training, or non-invasive ventilation at night may be suggested. Speech therapy may help with swallowing or voice control.Nutritional counselling
A dietitian can help build a balanced diet that keeps weight in a healthy range. Extra body weight puts more stress on weak feet and ankles, making walking and balance harder. For those with kidney involvement (from INF2), a kidney-friendly diet may be needed.Kidney monitoring and nephrology follow-up
Because INF2 mutations can also damage the kidney filters (FSGS), regular urine and blood tests are often recommended. If protein appears in the urine, an early visit to a kidney specialist (nephrologist) can help slow kidney damage.PubMed+2Wiley Online Library+2Genetic counselling for the family
A genetic counsellor explains how CMT1F is inherited, the chance of passing it to children, and options for family planning. They also help relatives understand their own risk and whether to consider genetic testing.Patient and family education
Clear information about CMT1F helps families recognize early changes, understand tests, and make shared decisions with doctors. Good education reduces fear, myths, and confusion and supports better long-term planning.Support groups and peer communities
Talking with other people who live with CMT helps reduce loneliness and gives practical ideas for daily life. CMT organisations often provide education days, online forums, and advocacy for better care.Charcot-Marie-Tooth Association+2Charcot-Marie-Tooth Disease+2Vocational and school rehabilitation
Specialists can help choose school subjects, job types, and work environments that match the person’s abilities. They may arrange special equipment or task changes so the person can stay in education or work.Regular review in a multidisciplinary CMT clinic
Combining neurology, physio, OT, orthotics, surgery, nephrology (kidneys), and psychology in one clinic leads to better long-term outcomes. Each visit allows early adjustment of braces, exercises, and support as the condition slowly changes.PMC+1
Drug treatments
There is no drug yet that cures or stops CMT1F itself. Almost all medicines are used to treat symptoms such as neuropathic pain, muscle stiffness, mood changes, or kidney problems. Many of these drugs are approved by the FDA for other conditions (for example, diabetic neuropathy or spasticity) and may be used off-label in CMT with specialist guidance.PMC+1
Dose ranges below are typical adult ranges from FDA labels for similar conditions, not personal prescriptions. Children and teenagers often need different doses, or may not be eligible at all. Always follow your own doctor’s advice.
I will focus on 10 key drug groups that are most commonly used and best supported by evidence for neuropathic pain and related symptoms.
Pregabalin (for nerve pain)
Pregabalin is an anti-seizure medicine that calms over-excited pain nerves. In adults it is FDA-approved for neuropathic pain in diabetic neuropathy, post-herpetic neuralgia, and spinal cord injury. Usual adult doses for neuropathic pain are 150–600 mg per day in divided doses, adjusted for kidney function. It can reduce burning, tingling, and shooting pains but may cause dizziness, sleepiness, weight gain, and swelling.FDA Access Data+3FDA Access Data+3FDA Access Data+3Gabapentin (for nerve pain)
Gabapentin is another anti-seizure drug used widely for nerve pain. It is FDA-approved for post-herpetic neuralgia in adults and partial seizures. Typical neuropathic pain doses range from about 900–3600 mg per day, split into three doses, slowly increased as tolerated. It can ease burning and electric-shock pain but may cause sleepiness, dizziness, and swelling.FDA Access Data+3FDA Access Data+3FDA Access Data+3Duloxetine (SNRI antidepressant for neuropathic pain)
Duloxetine is an antidepressant that blocks re-uptake of serotonin and noradrenaline and is FDA-approved for diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain, as well as anxiety and depression. Usual adult doses are 60–120 mg once daily. It can improve mood and nerve pain, but side effects may include nausea, dry mouth, sleep changes, and, rarely, liver or blood pressure problems.FDA Access Data+4FDA Access Data+4FDA Access Data+4Tricyclic antidepressants (e.g., amitriptyline)
Low-dose tricyclic antidepressants like amitriptyline are often used at night to treat neuropathic pain and help sleep. Typical adult pain doses start around 10–25 mg at night, slowly increasing if needed, but much higher doses are used for depression. They may help stabbing and burning pain, but can cause dry mouth, constipation, drowsiness, weight gain, heart rhythm changes, and are not suitable for everyone.FDA Access Data+2FDA Access Data+2Topical lidocaine patches or gels
Lidocaine patches (for example, 5% patches) are FDA-approved for post-herpetic neuralgia and sometimes used off-label for localized neuropathic pain in feet or hands. They numb the skin and superficial nerves without causing whole-body side effects. Patches are usually worn for up to 12 hours in 24. Skin irritation is the main side effect.FDA Access DataTopical capsaicin creams or patches
High-concentration capsaicin patches (8%) and lower-dose creams reduce pain by depleting a pain transmitter (substance P) from nerve endings. They may help localized burning pain in the feet. Application can cause strong burning or redness at first, so they must be used under medical guidance.Non-steroidal anti-inflammatory drugs (NSAIDs) and paracetamol
Ibuprofen, naproxen, or simple paracetamol do not treat nerve pain very well, but they can reduce muscle or joint pain from overuse, deformities, or surgery. They should be used at the lowest effective dose and shortest duration because of risks to the stomach, kidney, and heart, especially if INF2-related kidney disease is present.Baclofen (for stiffness and muscle spasms)
Baclofen is a GABA-B receptor agonist used for spasticity from multiple sclerosis and spinal cord disease. In CMT it may sometimes be tried if there are painful muscle spasms. Adult oral doses are usually started very low (for example 5–10 mg three times daily) and slowly increased. Sudden stopping can be dangerous, and side effects include drowsiness, weakness, and confusion.FDA Access Data+3FDA Access Data+3FDA Access Data+3Simple sleep or anxiety medicines (short term, with caution)
Chronic pain and disability can cause insomnia and anxiety. In some adults, doctors may prescribe short-term sleep aids or anxiety medicines, but these are used very carefully because of dependence, memory problems, and daytime drowsiness. Behavioural sleep strategies are usually tried first.Kidney-protective medicines (if FSGS or kidney damage)
If INF2-related CMT1F is associated with kidney disease (protein in the urine), nephrologists may prescribe medicines like ACE inhibitors or ARBs to reduce protein leakage and protect kidney function. These drugs lower blood pressure inside kidney filters and can slow kidney damage, but need regular blood and potassium checks.PubMed+2Wiley Online Library+2
Dietary molecular supplements
No supplement has been proven to cure CMT1F. Some are studied in general nerve health or diabetic neuropathy. Evidence is usually small or mixed, so all supplements should be discussed with a doctor, especially if there is kidney disease.PMC+1
Vitamin B1 (thiamine or benfotiamine) – supports energy production in nerves. Low levels can cause neuropathy. Supplements are often 50–150 mg/day, but doses vary.
Vitamin B6 (pyridoxine) – important for nerve signalling, but too much can actually damage nerves. If used, doses are usually modest (often ≤50 mg/day) and monitored.
Vitamin B12 (methylcobalamin) – needed for myelin repair. In deficiency, typical treatment is injections or high-dose oral tablets (e.g., 1,000 µg/day).
Folate (vitamin B9) – supports DNA and nerve cell health; used if blood tests show low levels.
Vitamin D – important for bone and muscle health; deficiency is common and can worsen weakness and falls. Doses depend on blood levels.
Omega-3 fatty acids (fish oil or algae oil) – have anti-inflammatory effects and may support nerve membranes; usual doses are 1–2 g of EPA/DHA daily, but must be balanced with bleeding risk.
Alpha-lipoic acid – an antioxidant studied in diabetic neuropathy; some trials show modest pain relief. Doses in studies are often 600 mg/day, but long-term safety in CMT is less clear.
Acetyl-L-carnitine – involved in energy handling in nerve and muscle cells; small studies suggest possible benefit in some neuropathies.
Coenzyme Q10 – supports mitochondria (energy factories) and may help fatigue in some conditions.
Magnesium – may help muscle cramps in some people, but high doses can affect heart rhythm and kidneys, especially if kidney function is reduced.
For all of these, the exact dose and need should be based on blood tests and medical advice, not self-treatment.
Regenerative and stem-cell-related approaches
For CMT1F, no regenerative or stem-cell drug is approved. Researchers are exploring several possibilities mainly in other CMT types; these may or may not help CMT1F in the future.Clinical Trials Register+6PMC+6Charcot-Marie-Tooth Disease+6
Gene-targeted therapies
Approaches like gene silencing, gene addition, or gene editing aim to correct or balance the faulty gene. Most work so far focuses on the PMP22 gene in CMT1A, not INF2, but the same ideas might later be studied for CMT1F.PXT3003 (experimental combination drug for CMT1A)
PXT3003 combines baclofen, naltrexone, and D-sorbitol to reduce over-expression of PMP22. Phase 2 and early Phase 3 studies in CMT1A showed some benefits, but later large trials had mixed results. It is not yet approved but shows how disease-modifying drugs may develop.Labiotech.eu+6PMC+6NIHR Innovation Observatory+6Neurotrophic growth factors
Lab and early clinical studies are testing growth factors like NT-3 that support nerve survival and regrowth. Delivery methods (injections or gene therapy) and side effects are still being studied.Stem-cell transplantation
Experimental research is exploring whether certain stem cells can support or replace damaged nerve support cells or muscle. At present, this is research only and not standard care for CMT.Anti-oxidant and mitochondrial-targeting drugs
Some experimental drugs aim to protect mitochondria and reduce oxidative stress in nerve cells. They may work like “advanced” versions of some supplements but are still in trials.INF2-specific gene or RNA therapies (future idea)
Because INF2 mutations also affect kidney cells, future research may look at dual treatments that protect both nerve and kidney tissue. For now, this remains theoretical.
Surgical treatments
Surgery does not fix the gene problem, but it can correct deformities and improve function or relieve pain. It is usually considered after braces and therapy are fully tried.Charcot-Marie-Tooth Disease+2eMedicine+2
Tendon transfer surgery
In this procedure, a working tendon is moved to help a weak movement (for example, lifting the foot). The surgeon re-attaches the tendon so it can help correct foot drop or toe deformity. The goal is to improve walking and reduce tripping.Osteotomy (bone-cutting)
When bones in the foot are severely mis-shaped (e.g., high arches, twisted heel), the surgeon cuts and re-positions the bone to create a more balanced foot. This spreads pressure more evenly and helps braces work better.Triple arthrodesis (foot joint fusion)
In very stiff, painful, or severely deformed feet, three main joints in the foot are fused (joined) together in a better position. This reduces pain and improves stability, but the foot becomes less flexible.Spinal surgery for scoliosis
Weak trunk muscles can lead to scoliosis. If the curve is severe and braces are not enough, spinal fusion surgery may be needed. Correcting the curve can improve posture, breathing, and sitting balance.Hand surgery (for clawing or contractures)
When fingers bend into fixed positions, tendon releases or transfers can improve hand opening and grip. This may make self-care easier and reduce pain.
Prevention and self-care
You cannot prevent the genetic cause of CMT1F, but you can reduce complications and slow secondary problems:
Protect your feet with well-fitting shoes and check them daily for blisters or sores.
Avoid walking barefoot on hard or unsafe surfaces to prevent injuries.
Keep body weight in a healthy range to reduce stress on weak feet and ankles.nhs.uk+2Mayo Clinic+2
Do regular, gentle exercise as advised by your therapist; avoid over-tiring or high-impact sports.
Avoid smoking and limit alcohol, because both can damage nerves and kidneys.
Manage other health conditions, especially diabetes and high blood pressure, as they can worsen neuropathy and kidney disease.FDA Access Data+2PubMed+2
Ask your doctor before taking new medicines, especially chemotherapy or certain antibiotics that may harm nerves or kidneys.
Keep vaccinations up to date to reduce severe infections that could worsen weakness.
Follow kidney monitoring schedules (urine and blood tests) if you have an INF2 mutation.
Keep regular appointments with your neurologist, physio, and orthotic team to adjust braces and therapy as you grow or change.
When to see a doctor urgently
You should contact a doctor promptly (or urgent/emergency care, depending on severity) if:
You suddenly cannot walk, stand, or climb stairs as before.
You have new serious trouble breathing, speaking, or swallowing.
You notice fast worsening of weakness or severe new pain in days or weeks (faster than the usual slow change in CMT).
You have repeated falls, head injuries, or fractures.
You see foot sores that do not heal or look infected (red, hot, swollen, or oozing).
You have new swelling of legs, frothy urine, or very low urine output – possible signs of kidney problems linked to INF2.PubMed+2Wiley Online Library+2
You have strong mood changes, severe sadness, or thoughts of harming yourself – these always need quick help and support.
Any medicine causes serious side effects such as rash, breathing trouble, severe dizziness, or changes in mood or thinking.
What to eat and what to avoid
There is no special “CMT1F diet,” but a healthy, nerve- and kidney-friendly diet supports overall health and function.
Helpful to eat:
Plenty of vegetables and fruits – give vitamins, minerals, and antioxidants to support general cell and nerve health.
Lean proteins (fish, poultry, beans, lentils, tofu) – support muscle repair and strength.
Healthy fats (olive oil, nuts, seeds, avocado, oily fish) – include omega-3s which may help inflammation.
Whole grains (brown rice, oats, whole-wheat bread) – keep energy steady and help weight control.
Adequate fluids – water and low-sugar drinks help kidney function and general health.
Better to limit or avoid:
Excess salt – high-salt diets can strain kidneys and raise blood pressure, especially important if INF2-related kidney disease is present.
Sugary drinks and sweets – raise weight and blood sugar, increasing risk of diabetes and further nerve damage.
Highly processed fast foods and trans fats – promote inflammation and weight gain.
Heavy alcohol use – directly toxic to nerves and harmful to the liver and kidneys.
Very high-dose unmonitored supplements – some vitamins (especially B6) and herbs can damage nerves or kidneys when taken in large amounts without medical oversight.FDA Access Data+2PubMed+2
A dietitian, especially one familiar with kidney-friendly diets, can give a personalised plan.
Frequently asked questions (FAQs)
Is CMT1F curable?
No. At present there is no cure. Treatment focuses on exercises, braces, pain control, surgery when needed, and careful monitoring of nerves and kidneys.Is CMT1F always linked to the INF2 gene?
Many cases of CMT1F involve changes in the INF2 gene, but genetics is complex and new variants are still being studied. Genetic testing and counselling can give the best answer for each family.kireports.org+3PubMed+3OUP Academic+3Will everyone with CMT1F get kidney disease?
No. Some people with INF2 mutations develop kidney problems (FSGS), while others have mainly nerve symptoms. Regular urine and blood tests are important to catch problems early.Does CMT1F shorten life expectancy?
Many people with CMT live near-normal lifespans, especially with good care and prevention of complications. Severe kidney disease, lung problems, or falls and fractures can affect health, so monitoring is important.Can children or teenagers with CMT1F play sports?
Often yes, but low-impact activities (swimming, cycling, gentle walking, yoga) are safer than contact or high-impact sports. A physiotherapist can help choose safe activities.Will I need braces forever?
Many people with CMT use AFOs or other braces long term. The type may change over time as weakness changes. If surgery is done successfully, brace needs may decrease or change.Can pregnancy make CMT1F worse?
Some women report more fatigue and weakness during pregnancy, while others notice little change. Planning pregnancy with a neurologist and obstetrician, and genetic counselling about inheritance risk, is helpful.Can CMT1F affect my hands?
Yes. Weakness and wasting often start in the feet but may later affect hands, causing trouble with buttons, writing, or fine tasks. OT, hand splints, and adaptive tools can help.Is pain always present in CMT1F?
Not always. Some people mainly have weakness and numbness; others have burning or electric-shock pain. Nerve pain medicines, physical therapy, and psychology support can reduce its impact.Physiopedia+2PMC+2Are there clinical trials for CMT?
Yes. Trials test new drugs, gene therapies, and other treatments, especially for CMT1A and some other types. People with CMT1F can often register in CMT research networks and may be invited to suitable studies.Charcot-Marie-Tooth Disease+2PMC+2Should every person with CMT1F take supplements?
Not always. Supplements should be based on blood tests and medical advice. Too many or high-dose supplements can sometimes cause harm.Can CMT1F be misdiagnosed as another neuropathy?
Yes. Many neuropathies look similar. Nerve tests, family history, and genetic testing are often needed to make a clear diagnosis.MedlinePlus+1Is CMT1F contagious?
No. It is inherited and cannot be caught from another person.Can I still work or study with CMT1F?
Many people study and work successfully with adjustments like ergonomic chairs, adapted keyboards, flexible schedules, and accessible buildings. Vocational rehabilitation and school disability services can help.What is the most important thing I can do right now?
The most helpful steps are: get regular follow-up with a neurologist, start or continue physiotherapy, use braces or orthotics if recommended, protect your feet, and ask about kidney monitoring and genetic counselling for you and your family.
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: December 29, 2025.
